What happened with RMTI today?
No read yet
Uses news and trading volume to explain the day’s move and how it relates to the market.
Stop guessing. Get the call, a three-month target price, the best and worst cases, and a source for every claim.
Rockwell Medical supplies dialysis clinics and hospitals with liquid and dry acid and bicarbonate concentrates used in hemodialysis. Concentrate sales account for essentially all its revenue, and most products are sold for use in the United States. Dialysis providers and distributors pay for the products under purchase agreements. Rockwell delivers most U.S. orders through its Rockwell Transportation truck fleet, with outside carriers and distribution partners handling the rest.
DaVita remains an important customer after substantially reducing its purchases, while other large domestic and international customers also account for a significant share of business. Demand depends on continued use of in-center hemodialysis. What Rockwell earns from these sales also depends on manufacturing and delivery costs and its ability to adjust prices: some customer agreements limit when or how much prices can rise.
Its concentrate products require FDA clearance or approval before U.S. marketing, and manufacturing must meet ongoing quality requirements. DaVita’s investment agreement also restricts the types of additional debt Rockwell can take on without DaVita’s consent.
The risk section is the longest, dullest part of the filing. This keeps only what can really hurt you: where it hits, how hard, when it plays out.
Every company claims an edge. Each one is checked against hard numbers like margins and returns: which hold, and which line gives way first.
Rockwell Medical’s results hinge on dialysis providers’ purchasing volumes and concentrate prices, with Nipro Medical Corporation another principal concentrate competitor not shown here.
DaVita buys Rockwell Medical’s concentrates to treat dialysis patients, and its reduced purchases drove Rockwell’s 2025 sales decline: sales to DaVita fell by $34.6 million. Watch purchasing under the supply agreement extended through December 31, 2026, which raised prices but does not itself signal a recovery in volume.
Fresenius Medical Care both competes with Rockwell Medical for dialysis-concentrate sales and buys Rockwell concentrates for its own dialysis business. Its sales of concentrates to dialysis providers show the competing side of the relationship, while purchases for its clinics contribute to Rockwell’s revenue.
CorMedix and Rockwell Medical both depend on U.S. dialysis demand and providers’ spending on treatment supplies: CorMedix sells DefenCath to prevent infections in hemodialysis catheters, while Rockwell sells concentrates used in treatments. DefenCath sales in outpatient hemodialysis settings offer a view of spending by the same customer group, though on a different product.
DaVita Inc. earningsDVA
DaVita's report will show how its dialysis treatments and medical-supply spending are changing, offering clues about the purchasing backdrop for this major Rockwell Medical customer.
Read DaVita's dialysis treatment volume alongside its medical-supply spending. More treatments without a pullback in supply spending would point to a supportive business and purchasing backdrop for Rockwell Medical's concentrates; fewer treatments or tighter supply spending would point to pressure. DaVita's report does not identify purchases from Rockwell Medical, so these are demand clues, not proof of its orders.
Fresenius Medical Care AG earningsFMS
Fresenius Medical Care's report will show changes in its products business and dialysis treatment volume, offering separate clues to its competitive pressure on Rockwell Medical and demand from its own clinics.
Compare Fresenius Medical Care's products-business sales with treatment volume at its clinics. Products sales strengthening relative to treatment volume could signal a more forceful rival in sales to dialysis providers, making it harder for Rockwell Medical to win business; steady clinic treatment volume with weaker products sales would offer less evidence of rising competitive pressure, while still pointing to demand at Fresenius's clinics. The products business does not isolate concentrate sales, and treatment volume does not establish purchases from Rockwell Medical, so the conclusion is about the direction of competition and demand, not specific orders.
Rockwell Medical, Inc. earningsThis company
Rockwell Medical's report will show whether product sales can make up for reduced DaVita purchases and support profit after product costs.
Read product sales alongside gross margin, the share of sales left after product costs. Stabilizing or recovering sales with a steady or rising margin would show that demand from other customers, pricing and cost control are helping offset the reduced DaVita business. Further sales declines or a falling margin would show that replacement sales or cost control are not yet enough, leaving the recovery incomplete.
